Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal
COPENHAGEN (Reuters) - Danish drugmaker Lundbeck said on Friday it had agreed to buy Prexton Therapeutics, which has drug candidate foliglurax in phase II testing for treatment of Parkinson's disease.
from Reuters: Health News http://reut.rs/2FED7zQ
http://bit.ly/2zwRqiM
March 16, 2018
|
Labels:
health,
Reuters: Health News
|
This entry was posted on March 16, 2018
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.